Seasonal Allergic Rhinitis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the SQ Grass SLIT-tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis
Verified date | December 2015 |
Source | Abbott |
Contact | n/a |
Is FDA regulated | No |
Health authority | Russia: Ministry of Health of the Russian Federation |
Study type | Interventional |
To investigate the immunologic effects and safety of 60-day treatment of the Standardized Quality units (SQ) grass Sublingual immunotherapy (SLIT)-tablet in adult subjects with grass pollen-induced allergic rhinoconjunctivitis in a double-blind, placebo-controlled study.
Status | Completed |
Enrollment | 107 |
Est. completion date | March 2015 |
Est. primary completion date | March 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - clinical history consistent with grass pollen-induced allergic rhinoconjunctivitis. - Use of symptomatic treatment of grass pollen-induced allergic rhinoconjunctivitis. - Positive skin prick test response (wheal diameter =3 mm) to Phleum pratense. - If asthma, daily use of Inhaled corticosteroid (ICS) should be =400 microgram budesonide or equivalent - Moderate or higher level of Phleum pratense specific IgE (Immunoglobulin E) (defined as =IgE Class 2; or =0.70 Kilo Units/liter (kU/L)) Exclusion Criteria: - Reduced lung function (defined as FEV1 < 70% (FEV1=Forced Expiratory Volume in 1 second) of predicted value after adequate pharmacologic treatment) measured at Visit 1 and Visit 2 - Clinical history of uncontrolled asthma within 3 months prior to the screening visit |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Russian Federation | Research facility ID ORG-001005 | Moscow | |
Russian Federation | Research facility ID ORG-001006 | Moscow | |
Russian Federation | Research facility ID ORG-001009 | Moscow | |
Russian Federation | Research facility ID ORG-001014 | Moscow | |
Russian Federation | Research facility ID ORG-001016 | Moscow | |
Russian Federation | Research facility ID ORG-001018 | Moscow | |
Russian Federation | Research facility ID ORG-001085 | Moscow | |
Russian Federation | Research facility ID ORG-001086 | Moscow | |
Russian Federation | Research facility ID ORG-001015 | Samara | |
Russian Federation | Research facility ID ORG-001021 | Saratov | |
Russian Federation | Research facility ID ORG-001017 | Smolensk | |
Russian Federation | Research facility ID ORG-001007 | St. Petersburg | |
Russian Federation | Research facility ID ORG-001008 | St. Petersburg | |
Russian Federation | Research facility ID ORG-001019 | St. Petersburg | |
Russian Federation | Research facility ID ORG-001020 | Ufa |
Lead Sponsor | Collaborator |
---|---|
Abbott |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Primary Efficacy Endpoint is Change From Baseline to End of Treatment of Phleum Pratense Specific Immunoglobulin G4 (IgG4) in Serum | measurement of IgG4 in serum | baseline versus end of treatment (approx. 60 days) | No |
Secondary | Change of Phleum Pratense Specific Immunoglobulin E (IgE) From Baseline to End of Treatment | measurement of IgE in serum | baseline versus end of treatment (approx. 60 days) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01171664 -
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects
|
Phase 2 | |
Terminated |
NCT01337323 -
Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting
|
N/A | |
Completed |
NCT00784732 -
A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber
|
Phase 2 | |
Completed |
NCT00578929 -
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
|
Phase 3 | |
Completed |
NCT00619827 -
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
|
Phase 1 | |
Completed |
NCT00209365 -
The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit
|
N/A | |
Terminated |
NCT00223587 -
Seasonal Allergic Rhinitis and Driving Ability
|
Phase 4 | |
Completed |
NCT00637455 -
Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel
|
Phase 4 | |
Completed |
NCT00963599 -
Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)
|
Phase 3 | |
Recruiting |
NCT05346718 -
Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis
|
N/A | |
Completed |
NCT06126952 -
Azelastine Allergen Chamber - Onset of Action Study
|
Phase 2 | |
Completed |
NCT01940146 -
Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
|
Phase 2 | |
Completed |
NCT01230619 -
Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis
|
Phase 2 | |
Completed |
NCT00574210 -
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
|
Phase 2 | |
Completed |
NCT00561717 -
A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis
|
Phase 4 | |
Completed |
NCT00405899 -
Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections
|
N/A | |
Completed |
NCT00443495 -
Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis
|
Phase 1/Phase 2 | |
Completed |
NCT00420082 -
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
|
Phase 2 | |
Completed |
NCT03097432 -
Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment
|
N/A | |
Completed |
NCT05540717 -
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
|
Phase 3 |